

iDose® TR (travoprost intracameral implant)

When requesting iDose® TR (travoprost intracameral implant), the individual requiring treatment must be diagnosed with the following FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-Approved Indication

iDose TR is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Coverage Guidelines

Reduction of intraocular pressure (IOP) with open-angle glaucoma (OAG) or ocular hypertension (OHT)

The individual must meet all of the following criteria for authorization:

- Is 18 years of age or older;
- Is not receiving re-treatment of eye(s) previously treated with iDose TR;
- Has experienced inadequate efficacy or severe adverse event(s) to at least two ophthalmic prostaglandins (as monotherapy or concomitant therapy) for the treatment of open-angle glaucoma or ocular hypertension (e.g., bimatoprost ophthalmic solution, latanoprost ophthalmic solution, travoprost ophthalmic solution, latanoprostene bunod ophthalmic solution, tafluprost ophthalmic solution, omidenepag isopropyl ophthalmic solution);
- Has experienced inadequate efficacy or severe adverse event(s) to at least two ophthalmic products (as monotherapy or concomitant therapy) from two different pharmacological classes for the treatment of open-angle glaucoma or ocular hypertension (e.g., beta-blockers, alpha-agonist [brimonidine], carbonic anhydrase inhibitors, rho kinase inhibitor [netarsudil]);
- iDose TR is administered by or under the supervision of an ophthalmologist.

Approval duration: one time use in each treated eye (a total of two implants)

Dosing Recommendation

For ophthalmic intracameral administration only.

The recommended dose is one iDose TR implant per treated eye, a total of two implants per patient.

References

1. iDose® TR intracameral implant [prescribing information]. San Clemente, CA: Glaukos; December 2023.
2. Boyd K. Glaucoma. Available at: <https://www.aao.org/eye-health/diseases/what-is-glaucoma>. Last reviewed, December 4, 2023. Accessed on February 3, 2025.
3. Gedde SJ, Vinod K, Wright MW, et al. Primary open-angle glaucoma Preferred Practice Pattern® guidelines. The American Academy of Ophthalmology. 2020. Available at: <https://www.aao.org/education/preferred-practice-pattern/primary-open-angle-glaucoma-ppp>. Accessed on February 3, 2025.
4. Durysta® [prescribing information]. North Chicago, IL: AbbVie; October 2024.